Conversely, the subgroup “AML with mutated chromatin, RNA-splicing genes, or both” is more consistent as an adverse prognostic group, at least among the five genetic mutations we reviewed here: RUNX1, MLLPTD, ASXL1, BCOR, and PHF6. This evidence concerns the gene PHF6 and acute myeloid leukemia.